Building K Production Will Serve Peptide And Oligonucleotide Therapies

Key Takeaways

• Significant expansion in large-scale manufacturing and process automation positions Bachem for outsized growth and improved margins amid rising demand for peptide and oligonucleotide drugs.
  
• Strong long-term customer partnerships and leadership in advanced therapeutics offer recurring, less volatile revenue and structural advantage as biopharma outsourcing intensifies.
  
• Large investment needs, currency risk, industry price pressures, and reliance on timely capacity expansion threaten Bachem's financial flexibility, margins, and future growth prospects.

Catalysts

Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.

• Bachem's substantial investment in expanding large-scale manufacturing capacity-particularly with the new Building K expected to enter GMP production in 2025 and begin significant revenue contribution in 2026-positions the company to capture accelerating demand from high-growth peptide and oligonucleotide drug markets, supporting outsized future revenue growth.
  
• The rapidly expanding pipeline of peptide and oligonucleotide therapeutics across multiple indications, including the massive projected growth in the anti-obesity market, provides strong, multi-year visibility for outsourcing demand; Bachem's leadership in these modalities and the current supply-demand imbalance offer the potential for sustained volume and pricing power, boosting both revenue and margins.
  
• Continuous operational excellence initiatives, such as harmonization of processes across sites, implementation of shift work, network production, and increasing automation, are already delivering material cost efficiencies; these trends should drive further improvement in net margins and earnings as new capacity ramps.
  
• The expansion of long-term customer partnerships-underscored by high visibility of prepayments from major pharma clients-aligns Bachem for recurring business, reduced revenue volatility, and consistent margin expansion as global biopharma intensifies outsourcing of complex molecule production.
  
• Early, proactive investment in next-generation oligonucleotide manufacturing, with a healthy backlog of projects and clear order visibility, positions Bachem to benefit disproportionately as regulatory approvals increase and the global acceptance of these advanced therapeutics widens the addressable market, underpinning structural top-line growth.

Bachem Holding Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Bachem Holding's revenue will grow by 25.3% annually over the next 3 years.
• Analysts assume that profit margins will shrink from 21.4% today to 19.4% in 3 years time.
• Analysts expect earnings to reach CHF 264.8 million (and earnings per share of CHF 3.54) by about July 2029, up from CHF 148.8 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as CHF322.9 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 26.6x on those 2029 earnings, down from 37.1x today. This future PE is lower than the current PE for the GB Life Sciences industry at 36.5x.
• Analysts expect the number of shares outstanding to grow by 0.21% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 4.63%, as per the Simply Wall St company report.

Risks

• Significant ongoing and future CapEx requirements (including CHF 400+ million in 2025 and continued large-scale investments at multiple sites) could put sustained pressure on free cash flow and increase reliance on external debt financing, raising the risk of reduced financial flexibility and potentially dilutive equity needs if internal cash generation lags.
  
• Heightened exposure to currency volatility, especially due to the strong Swiss franc and much of Bachem's revenue base in US dollars, is already impacting margins and net income (CHF 11 million FX loss in H1), and could weigh on future revenues and profitability if unfavorable exchange rate trends persist.
  
• Intensifying industry-wide efficiency improvements and automation (both by Bachem and its competitors) could lead to pricing pressure on long-term customer contracts, reducing gross margins if cost savings are passed on to customers or if customers demand lower prices as the industry becomes more commoditized.
  
• Heavy dependence on successful completion, regulatory approval, and commissioning of new manufacturing capacity (notably Building K and major US expansions) means that any delays, cost overruns, or regulatory setbacks could limit growth, lead to underutilization of assets, and pressure future earnings.
  
• Persistent and rising operational and financing costs-including ramp-up costs for new facilities, increased personnel to support growth, and growing debt service-could erode net margins, especially if revenue growth slows, industry pricing pressure intensifies, or macroeconomic/FX headwinds worsen.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of CHF81.4 for Bachem Holding based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CHF110.0, and the most bearish reporting a price target of just CHF52.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CHF1.4 billion, earnings will come to CHF264.8 million, and it would be trading on a PE ratio of 26.6x, assuming you use a discount rate of 4.6%.
• Given the current share price of CHF73.6, the analyst price target of CHF81.4 is 9.6% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.